Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as a 250 mg atovaquone / 100 mg proguanil tablet for oral use. It treats and prevents malaria infection in travelers, expatriates, and residents of endemic regions, and is indicated for both prophylaxis and treatment of acute malaria caused by Plasmodium species.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution through its extensive network of certified partners.

Malarone is an antiprotozoal medication used in the prevention and treatment of malaria caused by Plasmodium species.

- Prevention of malaria infection: provides prophylaxis for travelers and residents entering endemic areas. - Acute uncomplicated P. falciparum malaria: used to treat confirmed infection and achieve parasite clearance. - Acute uncomplicated P. vivax malaria: employed as part of therapy to eradicate blood‑stage parasites.

Malarone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset. - Abdominal pain: intermittent cramps. - Headache: transient. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Severe hypersensitivity: includes anaphylaxis. - Hepatotoxicity: elevated liver enzymes, jaundice. - Hemolytic anemia: especially in G6PD deficiency.

Before prescribing Malarone, consider the following precautions to ensure safe use.

- Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: avoid unless essential; drug excreted in milk. - G6PD deficiency: monitor for hemolysis. - Renal or hepatic impairment: dose adjustment may be required; assess function. - Concomitant antiretrovirals: evaluate for reduced efficacy. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Malarone can interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Rifampin: reduces atovaquone levels, may compromise efficacy. - Protease inhibitors (e.g., ritonavir): may increase atovaquone concentrations, risk toxicity. - CYP2C8 inhibitors (e.g., gemfibrozil): can raise proguanil levels.

Moderate Interactions (Monitor Closely): - Antacids or sucralfate: may decrease absorption of atovaquone. - Warfarin: may enhance anticoagulant effect. - St. John’s wort: may lower drug concentrations.